Format

Send to

Choose Destination
See comment in PubMed Commons below
J Subst Abuse Treat. 2013 Aug;45(2):222-6. doi: 10.1016/j.jsat.2013.02.005. Epub 2013 Mar 27.

Initiation of buprenorphine during incarceration and retention in treatment upon release.

Author information

1
The Miriam Hospital, Providence, RI, USA. nzaller@lifespan.org

Abstract

We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.

PMID:
23541303
PMCID:
PMC3690138
DOI:
10.1016/j.jsat.2013.02.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center